Medovex Corporation's Sam Blankenship Interviewed on the Emmy Award-Winning Big Biz Show


ATLANTA, GA--(Marketwired - Jul 23, 2015) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company's Director Product Development and Operations, Sam Blankenship, was recently a featured guest on the Emmy Award-winning nationally syndicated radio and TV show, Big Biz Show hosted by Bob "Sully" Sullivan.

The Live segment may be viewed here: The Big Biz Show

The Big Biz Show, hosted by Bob "Sully" Sullivan, is a nationally syndicated radio and TV show that talks current business, entrepreneurship and lifestyle-related issues with the movers and shakers in the business world. It's a laid-back approach to serious business issues with comedic commentary. The television show, referred to by the Wall Street Journal as "business with a bar room slant", is broadcasted on the Biz TV network, TiVo, Youtoo America and via the internet on Ustream. The radio version of the show can be heard on the Armed Forces Network, Biz Talk Radio, and CBS Radio, and brings in roughly 1.7 million radio listeners per week. It is also broadcasted to 40 million cable television homes weekly (Source: Biz Television, Armed Forces Radio, Business Talk Radio Network, CBS Radio, Arbitron 2013).

More information on the Big Biz Show -- Hosted by Bob "Sully" Sullivan, can be found by visiting http://BigBizShow.com.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information:

Medovex Corp.
Jason Assad
470-505-9905